S&P 500   3,087.01 (-0.20%)
DOW   27,691.49 (+0.04%)
QQQ   200.96 (-0.13%)
CGC   20.30 (-5.41%)
BABA   186.71 (-0.24%)
GE   11.35 (-1.48%)
T   39.37 (-0.03%)
F   9.08 (+0.44%)
ACB   3.62 (-4.99%)
PRI   129.23 (-0.37%)
BAC   33.18 (-0.24%)
DIS   136.74 (-0.88%)
S&P 500   3,087.01 (-0.20%)
DOW   27,691.49 (+0.04%)
QQQ   200.96 (-0.13%)
CGC   20.30 (-5.41%)
BABA   186.71 (-0.24%)
GE   11.35 (-1.48%)
T   39.37 (-0.03%)
F   9.08 (+0.44%)
ACB   3.62 (-4.99%)
PRI   129.23 (-0.37%)
BAC   33.18 (-0.24%)
DIS   136.74 (-0.88%)
Log in

iCAD Stock Price, Forecast & Analysis (NASDAQ:ICAD)

$6.78
-0.02 (-0.29 %)
(As of 11/11/2019 04:00 PM ET)
Today's Range
$6.72
Now: $6.78
$6.89
50-Day Range
$6.35
MA: $7.02
$7.95
52-Week Range
$2.50
Now: $6.78
$8.00
Volume33,788 shs
Average Volume134,266 shs
Market Capitalization$130.60 million
P/E RatioN/A
Dividend YieldN/A
Beta1.12
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy. It also offers digital mammography computer-aided detection (CAD) products, such as advanced image analysis and workflow solutions in breast imaging, which include PowerLook Mammo Detection, which detects and identifies suspicious masses and micro-calcifications; and PowerLook Advanced Mammography Platform, a computer server residing on a customer's network that receives patient studies from the imaging modality, performs CAD and density assessment analysis, and sends the CAD results to picture archiving and communication system and/or review workstations. In addition, the company's digital mammography CAD products comprise magnetic resonance imaging products to detect breast and prostate cancer; breast tomosynthesis systems; and advanced image analysis and workflow solutions in computed tomography (CT) colonography, including VeraLook that supports the detection of colonic polyps in conjunction with CT colonography. It serves hospitals, ambulatory care centers and free standing radiation oncology facilities, and other office-based uses through sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. iCAD, Inc. has a strategic partnership agreement with Invivo Corp. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was founded in 1984 and is headquartered in Nashua, New Hampshire.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorComputer and Technology
Current SymbolNASDAQ:ICAD
CUSIPN/A
Phone603-882-5200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$25.62 million
Book Value$0.40 per share

Profitability

Net Income$-9,020,000.00

Miscellaneous

Employees95
Market Cap$130.60 million
Next Earnings Date3/16/2020 (Estimated)
OptionableOptionable

Receive ICAD News and Ratings via Email

Sign-up to receive the latest news and ratings for ICAD and its competitors with MarketBeat's FREE daily newsletter.


iCAD (NASDAQ:ICAD) Frequently Asked Questions

What is iCAD's stock symbol?

iCAD trades on the NASDAQ under the ticker symbol "ICAD."

How were iCAD's earnings last quarter?

iCAD Inc (NASDAQ:ICAD) issued its quarterly earnings results on Wednesday, October, 30th. The technology company reported ($0.10) earnings per share for the quarter, meeting the consensus estimate of ($0.10). The technology company earned $7.86 million during the quarter, compared to analysts' expectations of $7.43 million. iCAD had a negative return on equity of 78.90% and a negative net margin of 46.85%. View iCAD's Earnings History.

When is iCAD's next earnings date?

iCAD is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for iCAD.

Has iCAD been receiving favorable news coverage?

Press coverage about ICAD stock has trended very negative this week, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. iCAD earned a news sentiment score of -3.2 on InfoTrie's scale. They also gave media stories about the technology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for iCAD.

Are investors shorting iCAD?

iCAD saw a drop in short interest during the month of October. As of October 31st, there was short interest totalling 566,500 shares, a drop of 5.2% from the September 30th total of 597,500 shares. Based on an average daily trading volume, of 95,900 shares, the days-to-cover ratio is presently 5.9 days. Approximately 3.4% of the shares of the company are sold short. View iCAD's Current Options Chain.

Who are some of iCAD's key competitors?

What other stocks do shareholders of iCAD own?

Who are iCAD's key executives?

iCAD's management team includes the folowing people:
  • Ms. Stacey M. Stevens, Pres (Age 51)
  • Mr. Michael S. Klein, Exec. Chairman & CEO (Age 65)
  • Mr. R. Scott Areglado, VP, Corp. Controller & Interim CFO (Age 55)
  • Mr. Jonathan Go, Chief Technology Officer (Age 56)
  • Ms. Annette L. Heroux, VP of Admin. (Age 62)

Who are iCAD's major shareholders?

iCAD's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Cadence Capital Management LLC (0.06%). View Institutional Ownership Trends for iCAD.

Which major investors are buying iCAD stock?

ICAD stock was bought by a variety of institutional investors in the last quarter, including Cadence Capital Management LLC. View Insider Buying and Selling for iCAD.

How do I buy shares of iCAD?

Shares of ICAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is iCAD's stock price today?

One share of ICAD stock can currently be purchased for approximately $6.78.

How big of a company is iCAD?

iCAD has a market capitalization of $130.60 million and generates $25.62 million in revenue each year. The technology company earns $-9,020,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis. iCAD employs 95 workers across the globe.View Additional Information About iCAD.

What is iCAD's official website?

The official website for iCAD is http://www.icadmed.com/.

How can I contact iCAD?

iCAD's mailing address is 98 SPIT BROOK ROAD SUITE 100, NASHUA NH, 03062. The technology company can be reached via phone at 603-882-5200 or via email at [email protected]


MarketBeat Community Rating for iCAD (NASDAQ ICAD)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  139 (Vote Outperform)
Underperform Votes:  144 (Vote Underperform)
Total Votes:  283
MarketBeat's community ratings are surveys of what our community members think about iCAD and other stocks. Vote "Outperform" if you believe ICAD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICAD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/11/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel